Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 6, 2004, Pages 536-544

  Zineh, Issam ^b   Beitelshees, Amber L ^b   Gaedigk, Andrea ^b   Walker, Joseph R ^b   Pauly, Daniel F ^b   Eberst, Kathleen ^b   Leeder, J Steven ^b   Phillips, Michael S ^b   Gelfand, Craig A ^b   Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; METOPROLOL;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; EDEMA; FATIGUE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERTENSION; LETHARGY; LIBIDO DISORDER; MALE; PARESTHESIA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; STEADY STATE; TITRIMETRY; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AREA UNDER CURVE; BLOOD PRESSURE; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 10044291653     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.08.020     Document Type: Article

References (41)

1. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
2. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldmanmd, G.S. Francis ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America Circulation 104 2001 2996 3007
3. R.J. Gibbons, J. Abrams, K. Chatterjee, J. Daley, P.C. Deedwania, J.S. Douglas ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168
4. T.J. Ryan, E.M. Antman, N.H. Brooks, R.M. Califf, L.D. Hillis, L.F. Hiratzka 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J Am Coll Cardiol 34 1999 890 911
5. E. Braunwald, E.M. Antman, J.W. Beasley, R.M. Califf, M.D. Cheitlin, J.S. Hochman ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina) J Am Coll Cardiol 40 2002 1366 1374
6. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents JAMA 248 1982 2004 2011
7. B.J. Materson, D.J. Reda, W.C. Cushman, B.M. Massie, E.D. Freis, M.S. Kochar Single-drug therapy for hypertension in men A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents N Engl J Med 328 1993 914 921
8. R. van der Does, U. Hauf-Zachariou, E. Pfarr, W. Holtbrugge, S. Konig, M. Griffiths Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris Am J Cardiol 83 1999 643 649
9. C.G. Regardh, G. Johnsson Clinical pharmacokinetics of metoprolol Clin Pharmacokinet 5 1980 557 569
10. S.S. Murthy, H.U. Shetty, W.L. Nelson, P.R. Jackson, M.S. Lennard Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol Biochem Pharmacol 40 1990 1637 1644
11. C. Sachse, J. Brockmoller, S. Bauer, I. Roots Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 1997 284 295
12. CYP2D6 allele nomenclature. Human Cytochrome P405 (CYP) Allele Nomenclature Committee Web site. Available from: URL:http://www.imm.ki.se/ CYPalleles/cyp2d6.htm. 2004. Accessed May 21, 2004.
13. F.R. Sallee, C.L. DeVane, R.E. Ferrell Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency J Child Adolesc Psychopharmacol 10 2000 27 34
14. T. Kapitany, K. Meszaros, E. Lenzinger, S.D. Schindler, C. Barnas, K. Fuchs Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia Schizophr Res 32 1998 101 106
15. M.G. Scordo, E. Spina, P. Romeo, M.L. Dahl, L. Bertilsson, I. Johansson CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients Eur J Clin Pharmacol 56 2000 679 683
16. W.H. Chou, F.X. Yan, J. de Leon, J. Barnhill, T. Rogers, M. Cronin Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness J Clin Psychopharmacol 20 2000 246 251
17. G.M. Murphy Jr, C. Kremer, H.E. Rodrigues, A.F. Schatzberg Pharmacogenetics of antidepressant medication intolerance Am J Psychiatry 160 2003 1830 1835
18. K.A. Phillips, D.L. Veenstra, E. Oren, J.K. Lee, W. Sadee Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 286 2001 2270 2279
19. D.W. Clark, A.K. Morgan, H. Waal-Manning Adverse effects from metoprolol are not generally associated with oxidation status Br J Clin Pharmacol 18 1984 965 967
20. H. Wuttke, T. Rau, R. Heide, K. Bergmann, M. Bohm, J. Weil Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects Clin Pharmacol Ther 72 2002 429 437
21. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol Clin Pharmacol Ther 74 2003 44 52
22. J.A. Johnson, B.S. Burlew Metoprolol metabolism via cytochrome P4502D6 in ethnic populations Drug Metab Dispos 24 1996 350 355
23. A. Gaedigk, R.R. Gotschall, N.S. Forbes, S.D. Simon, G.L. Kearns, J.S. Leeder Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data Pharmacogenetics 9 1999 669 682
24. A. Gaedigk, L.D. Bradford, K.A. Marcucci, J.S. Leeder Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans Clin Pharmacol Ther 72 2002 76 89
25. A. Gaedigk, D.L. Ryder, L.D. Bradford, J.S. Leeder CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism Clin Chem 49 2003 1008 1011
26. F. Broly, U.A. Meyer Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene Pharmacogenetics 3 1993 123 130
27. U.M. Zanger, J. Fischer, S. Raimundo, T. Stuven, B.O. Evert, M. Schwab Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6 Pharmacogenetics 11 2001 573 585
28. Y. Ramamoorthy, R.F. Tyndale, E.M. Sellers Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates Pharmacogenetics 11 2001 477 487
29. K.A. Marcucci, R.E. Pearce, C. Crespi, D.T. Steimel, J.S. Leeder, A. Gaedigk Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine Drug Metab Dispos 30 2002 595 601
30. R.G. Newcombe Two-sided confidence intervals for the single proportion: comparison of seven methods Stat Med 17 1998 857 872
31. M.S. Lennard, G.T. Tucker, J.H. Silas, S. Freestone, L.E. Ramsay, H.F. Woods Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers Clin Pharmacol Ther 34 1983 732 737
32. E. Spina, M.G. Scordo, C. D'Arrigo Metabolic drug interactions with new psychotropic agents Fundam Clin Pharmacol 17 2003 517 538
33. C. Guzey, A. Norstrom, O. Spigset Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion Ther Drug Monit 24 2002 436 437
34. B.A. Hamelin, A. Bouayad, J. Methot, J. Jobin, P. Desgagnes, P. Poirier Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity Clin Pharmacol Ther 67 2000 466 477
35. B.A. Sproule, S.V. Otton, S.W. Cheung, X.H. Zhong, M.K. Romach, E.M. Sellers CYP2D6 inhibition in patients treated with sertraline J Clin Psychopharmacol 17 1997 102 106
36. J.H. Silas, M.S. Lennard, G.T. Tucker, L.E. Ramsay, H.F. Woods Polymorphic metabolism of beta-adrenoceptor antagonists Br J Clin Pharmacol 17 Suppl 1 1984 11S 19S
37. A. Silvestri, P. Galetta, E. Cerquetani, G. Marazzi, R. Patrizi, M. Fini Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo Eur Heart J 24 2003 1928 1932
38. D.T. Ko, P.R. Hebert, C.S. Coffey, A. Sedrakyan, J.P. Curtis, H.M. Krumholz Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction JAMA 288 2002 351 357
39. W.A. Gattis, C.M. O'Connor, D.S. Gallup, V. Hasselblad, M. Gheorghiade Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial J Am Coll Cardiol 43 2004 1534 1541
40. D.T. Ko, P.R. Hebert, C.S. Coffey, J.P. Curtis, J.M. Foody, A. Sedrakyan Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials Arch Intern Med 164 2004 1389 1394
41. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF Jr, Schofield RS, et al. β-Adrenergic receptor polymorphisms and responses during titration of metoprolol CR/XL in heart failure. Clin Pharmacol Ther. In press 2005.